DPP-4 inhibitors for treating T2DM

由 E D’Andrea 著作 · 2023 · 被引用 33 次 — This comparative effectiveness study evaluates cardiovascular effectiveness and safety of SGLT2 inhibitors vs DPP-4 inhibitors in adults ...

Comparing all separation treatments, hydrolysates processed only by MF and UF show the best DPP-IV inhibition (59.5–60.0% at 1 mg/mL and 34.2–40.7% at 0.5 mg/mL) ...

由 M Takahashi 著作 · 2020 · 被引用 6 次 — DPP-4 inhibitors appear to be superior to α-GIs but inferior to GLP-1 analogues in preservation of beta-cell function assessed by either HOMA-β ...

由 K Chen 著作 · 2018 · 被引用 50 次 — Different DPP-4 inhibitors were used, including vildagliptin, sitagliptin, alogliptin, linagliptin and saxagliptin. The drop-out rate was ...

由 K Saini 著作 · 2023 · 被引用 24 次 — Comparison of DPP-4 inhibitor with various classes of antidiabetic agents. Sitagliptin was the first commercialized, orally active and selective DPP-4 inhibitor ...

Table 1Cost Comparison Table for DPP-4 Inhibitors and Other Second-Line Oral Drugs ; Sitagliptin (Januvia), 100 mg, tab, 2.9527, 100 mg daily ...

由 KM Munir 著作 · 2017 · 被引用 18 次 — In a meta-analysis comparing vildagliptin to sitagliptin, both demonstrated similar reductions in HbA1c, fasting plasma glucose and post-prandial glucose, but ...

2013年12月31日 — ... DPP-4 inhibitor、Type 2 diabetes mellitus ... Golightly LK, Drayna CC, McDermott MT: Comparative clinical pharmacokinetics of dipeptidyl peptidase ...